NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK
Clinical trials for NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK explained in plain language.
Never miss a new study
Get alerted when new NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK trials appear
Sign up with your email to follow new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a single drug halt devastating nerve attacks in NMOSD patients?
Disease control Recruiting nowThis study tests whether eculizumab can quickly reduce disability during an acute attack of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease that damages the optic nerve and spinal cord. About 110 adults who test positive for a specific antibody (AQP4-IgG…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK
Phase: PHASE2 • Sponsor: Tianjin Medical University General Hospital • Aim: Disease control
Last updated May 26, 2026 06:31 UTC
-
New drug combo may ease severe nerve attacks in rare disease
Disease control Recruiting nowThis study tests whether adding eculizumab to standard steroid therapy helps people with neuromyelitis optica spectrum disorder (NMOSD) recover better from sudden attacks. About 200 adults with a specific antibody (AQP4-positive) will be followed in real-world clinics. The goal i…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK
Phase: PHASE4 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated May 22, 2026 14:04 UTC